ClinicalTrials.Veeva

Menu

Spectroscopic Assessment of Intramyocardial Oxygen Saturation Feasibility During Open-heart Surgery

S

Spectrocor

Status

Completed

Conditions

Heart Valve Diseases
Coronary Artery Disease

Treatments

Device: Spectrocor device

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05479968
Safe-op 1.0

Details and patient eligibility

About

This traditional feasibility study aims to capture preliminary safety and effectiveness information on a near-final Investigational Device design to adequately plan the forthcoming pivotal study.

Full description

The study design is based on measuring the depth of ischemia during the operation, which is compared to the intraoperative and postoperative morbidity of the patient, especially to the dysfunction of the heart.

A qualified and experienced Monitor is assigned for the study to oversee and document the progress of the trial. The Monitor ensures the trial performance in accordance with the Protocol and Good Clinical Practice (GCP).

The trial team conforms to ISO 13485 quality standards and ISO 14155 GCP. Processes included in the monitoring activities are documented in the quality management system. Below are described the summaries of all these activities.

Source data will be collected and transferred into the electronic CRFs by site staff, and the collected data quality and the conformity to the Good Clinical Practice will be assessed by monitoring. Based on a risk assessment performed, a Data Monitoring Committee shall not be established.

Clinical Research Associate (CRA) is responsible for checking the accuracy and completeness of Case Report Form (CRF) entries, source documents, and other investigation-related records against each other. Other responsibilities of CRA, including detailed Source Data Verification (SDV), are documented by the clinical project manager (CPM) or head of clinical research (HCR)(both are sponsor's representatives). SDVs will be performed and documented during monitoring visits.

Monitoring planning, reporting, and visits are pre-defined and documented with pre-made templates per the sponsor's quality management system. Monitoring visits will be performed to cover data from all study participants, and according to QMS and the Standard Operation Procedures.

The monitoring shall ensure that all source documentation is precise and document control is exercised in all relevant documentation. The monitoring ensures, that the Adverse events are always reported and appropriate authorities or stakeholders are informed.

Enrollment

15 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any 18 to 90-year old patient scheduled for open-heart operation
  • The ability to understand the objective of the study and the risks involved.
  • Informed consent obtained, including the agreement to authorization to use the protected personal patient records according to privacy legislation.

Exclusion criteria

  • Inability to obtain an informed consent form
  • Patients included as vulnerable population according to Finnish Medical Research Act, including retarded, pregnant women, nursing mothers, prisoners, or forensic patients.

Trial design

15 participants in 1 patient group

Tissue Spectrometry group
Description:
The experimental group is subjected to testing the Specrocor Investigational Device.
Treatment:
Device: Spectrocor device

Trial contacts and locations

1

Loading...

Central trial contact

Peter Raivio, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems